Studies of Elevated Parathyroid Activity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00001277
Recruitment Status : Recruiting
First Posted : November 4, 1999
Last Update Posted : November 9, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) )

November 3, 1999
November 4, 1999
November 9, 2018
March 31, 1991
Not Provided
Evaluate natural history of hyperparathyroidism [ Time Frame: On-going ]
Not Provided
Complete list of historical versions of study NCT00001277 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Studies of Elevated Parathyroid Activity
Studies of Hyperparathyroidism and Related Disorders

Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism. This study will help researchers better understand the causes of hyperthyroidism and to evaluate and improve methods for diagnosis and treatment.

In this study, patients diagnosed with or suspected of having hyperparathyroidism will be selected to participate. In addition, patients with related conditions such as parathyroid tumors, will also be selected.

Subjects will be asked to provide blood and urine for testing to confirm their condition. They will then be surgically treated by removal of the parathyroid gland(s) (parathyroidectomy).

Subjects with parathyroid tumors will undergo several diagnostic tests to determine the exact location of the tumor as well as the tumor's activity. The tests may include; ultrasounds, nuclear scanning, CT scans, MRI, and specialized blood testing.

Sometimes parathyroidectomy leads to hypoparathyroidism. Options for treating the patients after the surgical procedure will also be addressed. Calcium and Vitamin D supplements are typically the mainstay of post parathyroidectomy therapy. Other potential treatments include transplanting the parathyroid gland(s) to other areas of the body.

Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment. The principal diagnostic components are calcium in serum and urine, parathyroid hormone in serum, and mutation tests on germline or tumor DNA. Patients with moderately to severe primary hyperparathyroidism will be treated. Treatment will be mainly by parathyroidectomy. Preoperative testing to localize parathyroid neoplasm(s) will be used usually and with more extended methods in cases with prior neck surgery. Other options are medications or no intervention. Patients with a hyperparathyroid syndrome may be managed for their extraparathyroid features (medical management or surgical treatment). Preoperative tumor localization tests will be selected according to clinical indications from the following: ultrasound, technetium-thallium scan, computerized tomography, magnetic resonance imaging, somatostatin receptor imaging, fine needle aspiration for parathyroid hormone assay, selective arteriogram, selective venous catheterization for parathyroid hormone assay. Options for management of postoperative hypocalcemia include calcium, vitamin D analogs, parathyroid autografts and synthetic parathyroid hormone. Research specimens may consist of blood or tumors. In addition, a substudy for patients with multiple endocrine neoplasia type 1 (MEN1) will assess the utility of two PET/CT scans with radiotracers (68Gallium-DOTATATE and 18F-DOPA).
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Hyperparathyroidism
  • Hypocalcemia
  • Parathyroid Neoplasm
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
  • Patients who have genetically confirmed MEN1 or clinical criteria of MEN1.
  • Age greater than age 18.
  • For females: Negative urine pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy


  • Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure or congestive cardiac failure
  • Patients unable or unwilling to give informed consent
  • Pregnant or lactating women: Pregnant women are excluded from this study because the effects of 68Ga-DOTATATE in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 68Ga-DOTATATE in the mother, women who are breastfeeding are also excluded from this study
  • Patients that have recognized concurrent active infection
  • Patients with exposure to, or usage of, any investigational product or device, excluding 18F-DOPA scans, within 30 days prior to dosing
  • Patients with known hypersensitivity to carbidopa, or who are concurrently taking a nonselective monoamine oxidase (MAO) inhibitor..
Sexes Eligible for Study: All
Child, Adult, Older Adult
Contact: William F Simonds, M.D. (301) 496-9299
Contact: Jenny E Blau, M.D. (301) 827-1930
United States
Not Provided
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) )
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not Provided
Principal Investigator: Jenny E Blau, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health Clinical Center (CC)
November 5, 2018